“The current study analyzed the correlation between BORIS mutations and the expression of the protein in breast cancer cases.”
Credit: 2023 Akhtar et al.
“The current study analyzed the correlation between BORIS mutations and the expression of the protein in breast cancer cases.”
BUFFALO, NY- June 5, 2023 – A new research paper was published in Oncotarget’s Volume 14 on May 26, 2023, entitled, “Association of mutation and expression of the brother of the regulator of imprinted sites (BORIS) gene with breast cancer progression.”
The brother of the regulator of imprinted sites (BORIS), 11 zinc-finger transcription factors, is a member of the cancer-testis antigen (CTA) family. It is mapped to chromosome number 20q13.2 and this region is genetically linked to the early onset of breast cancer.
In the current study, researchers Mohammad Salman Akhtar, Naseem Akhter, Arshi Talat, Raed A. Alharbi, Abdulmajeed A.A. Sindi, Faisal Klufah, Hanan E. Alyahyawi, Abdulmohsen Alruwetei, Abrar Ahmad, Mazin A. Zamzami, SVS Deo, Syed Akhtar Husain, Osama A. Badi, and Mohammad Jahir Khan from Al-Baha University, Jamia Millia Islamia, ITS Dental College, Qassim University, King Abdulaziz University, All India Institute of Medical Sciences (AIIMS), Henry Ford Health System, and Jawahar Lal Nehru University analyzed the correlation between BORIS mutations and the expression of the protein in breast cancer cases.
“The present study is to find out the mutations of BORIS genes in hot spot exons by PCR-SSCP and by automated DNA sequencing in breast cancer tissue samples along with adjacent normal samples.”
A population-based study including a total of 155 breast cancer tissue samples and an equal number of normal adjacent tissues from Indian female breast cancer patients was carried out. Mutations of the BORIS gene were detected by polymerase chain reaction-single standard confirmation polymorphisms (PCR-SSCP) and automated DNA sequencing and by immunohistochemistry for BORIS protein expression were performed. The observed findings were correlated with several clinicopathological parameters to find out the clinical relevance of associations.
“The BORIS mutations and high protein expression occur frequently in carcinoma of the breast suggesting their association with the onset and progression of breast carcinoma. Further, the BORIS has the potential to be used as a biomarker.”
Read the full paper: DOI: https://doi.org/10.18632/oncotarget.28442
Correspondence to: Mohammad Salman Akhtar
Emails: [email protected], [email protected]
Keywords: BORIS, breast cancer, mutation, transcription factor, PCR-SSCP
About Oncotarget: Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media:
- YouTube
- LabTube
- Soundcloud
Click here to subscribe to Oncotarget publication updates.
For media inquiries, please contact: [email protected].
Oncotarget Journal Office
6666 East Quaker Str., Suite 1A
Orchard Park, NY 14127
Phone: 1-800-922-0957 (option 2)
###
Journal
Oncotarget
DOI
10.18632/oncotarget.28442
Method of Research
Observational study
Subject of Research
Human tissue samples
Article Title
Association of mutation and expression of the brother of the regulator of imprinted sites (BORIS) gene with breast cancer progression
Article Publication Date
26-May-2023
